Exagen Inc. (NASDAQ:XGN) Short Interest Up 32.5% in January

Exagen Inc. (NASDAQ:XGNGet Free Report) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 11,000 shares, a growth of 32.5% from the January 15th total of 8,300 shares. Based on an average daily volume of 58,900 shares, the short-interest ratio is presently 0.2 days. Currently, 0.1% of the company’s stock are sold short.

Exagen Trading Up 1.4 %

NASDAQ XGN opened at $2.10 on Tuesday. The firm has a 50 day moving average of $1.91 and a two-hundred day moving average of $2.04. Exagen has a 52 week low of $1.33 and a 52 week high of $3.92. The company has a quick ratio of 4.83, a current ratio of 4.83 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $35.81 million, a PE ratio of -1.13 and a beta of 1.22.

Exagen (NASDAQ:XGNGet Free Report) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.19. The firm had revenue of $13.42 million during the quarter, compared to the consensus estimate of $10.33 million. Exagen had a negative net margin of 62.90% and a negative return on equity of 81.62%. As a group, research analysts expect that Exagen will post -1.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Exagen

A number of large investors have recently bought and sold shares of XGN. Perkins Capital Management Inc. grew its stake in Exagen by 92.8% in the 4th quarter. Perkins Capital Management Inc. now owns 508,905 shares of the company’s stock valued at $1,013,000 after acquiring an additional 245,000 shares during the last quarter. Stonepine Capital Management LLC grew its position in shares of Exagen by 14.7% during the third quarter. Stonepine Capital Management LLC now owns 1,203,491 shares of the company’s stock worth $2,912,000 after buying an additional 154,139 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its holdings in shares of Exagen by 8.9% during the second quarter. Silvercrest Asset Management Group LLC now owns 547,133 shares of the company’s stock valued at $1,587,000 after acquiring an additional 44,518 shares during the period. Advisors Capital Management LLC raised its stake in shares of Exagen by 66.2% during the third quarter. Advisors Capital Management LLC now owns 67,923 shares of the company’s stock valued at $143,000 after purchasing an additional 27,050 shares in the last quarter. Finally, UBS Group AG raised its position in Exagen by 3.9% in the third quarter. UBS Group AG now owns 136,813 shares of the company’s stock worth $370,000 after acquiring an additional 5,144 shares in the last quarter. Hedge funds and other institutional investors own 40.85% of the company’s stock.

Analyst Ratings Changes

Separately, William Blair reiterated an “outperform” rating on shares of Exagen in a research report on Tuesday, November 14th.

Get Our Latest Report on Exagen

Exagen Company Profile

(Get Free Report)

Exagen Inc develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

See Also

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.